专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008070296A3 SYSTEM AND METHOD FOR DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS 审中-公开
标题翻译：神经病理障碍诊断和治疗系统及方法
公开(公告)号：WO2008070296A3
公开(公告)日：2008-11-20
申请号：PCT/US2007081649
申请日：2007-10-17
申请人： RES FOUND MENTAL HYGIENE , CLELLAND JAMES D , CLELLAND CATHERINE L
发明人： CLELLAND JAMES D , CLELLAND CATHERINE L
IPC分类号： C12Q1/68 , C07H21/04 , C12P19/34
CPC分类号： C12Q1/6883 , A61K31/519 , A61K31/5415 , A61K31/7052 , A61K33/00 , A61K33/14 , A61K45/06 , C12Q1/68 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158 , G01N33/50 , G01N2800/302 , G01N2800/50 , A61K2300/00
摘要： An assay for a GCHl allele and associated genotype for the screening, prediction, diagnosis, prognosis, treatment and treatment response of psychiatric, neuropsychiatric, and neurological disorders, such as schizophrenia, schizoaffective disorder and bipolar disorder, and for defining treatments of such disorders. The presence of a variant in the GCHl gene, alone or in conjunction with a measurement of low or altered biopterin, or altered BH4 system measures, is used to screen for or diagnose subjects at high risk for developing a psychiatric, neuropsychiatric, or neurological disorders. The assay of the GCHl genotype, with or without biopterin or a BH4 or BH4 system assay, may also be used to determine antipsychotic or mood stabilizer medication, as well as other treatments. For subjects with an impaired BH4 system, treatments to increase or normalize biopterin, BH4, or the BH4 system can also be used, such as BH4 supplementation, lithium treatment, phenylalanine treatment, or other treatments and therapies.
摘要翻译：用于筛选，预测，诊断，预后，治疗和治疗精神病学，神经精神病学和神经系统疾病如精神分裂症，分裂情感障碍和双相性精神障碍的治疗反应的GCH1等位基因和相关基因型的测定，以及用于定义这些疾病的治疗。 GCH1基因中单独存在或与低或改变的生物蝶呤或改变的BH4系统测量结合使用的变体用于筛选或诊断发生精神病学，神经精神障碍或神经障碍的高风险患者。使用或不使用生物蝶呤或BH4或BH4系统测定的GCH1基因型的测定也可用于测定抗精神病药或情绪稳定剂药物以及其它治疗。对于具有受损BH4系统的受试者，也可以使用治疗以增加或标准化生物蝶呤，BH4或BH4系统，例如BH4补充，锂处理，苯丙氨酸治疗或其他治疗和疗法。

2. 发明申请

WO2005046667A2 SYSTEM A TRANSPORT INHIBITORS FOR TREATING OR PREVENTING NEUROPSYCHIATRIC DISORDERS 审中-公开
标题翻译：系统用于治疗或预防神经障碍性疾病的运输抑制剂
公开(公告)号：WO2005046667A2
公开(公告)日：2005-05-26
申请号：PCT/US2004036934
申请日：2004-11-05
申请人： RES FOUND MENTAL HYGIENE , JAVITT DANIEL C , SERSHEN HENRY
发明人： JAVITT DANIEL C , SERSHEN HENRY
IPC分类号： A61K31/198 , A61K31/551 , G01N33/68 , A61P25/00 , A61P25/18 , A61P25/24 , A61P25/28 , A61P25/30
CPC分类号： G01N33/6896 , A61K31/198 , A61K31/5513 , G01N2500/00
摘要： The invention relates to System A transport inhibitors, antagonists, derivatives, or mimetics thereof, and their use as compounds, drugs, or agents for the treatment or prevention of neuropsychiatric diseases, disorders, or conditions, including schizophrenia. Another embodiment of the invention relates to methods of identifying or screening for such System A transport inhibitors for the treatment or prevention of neuropsychiatric diseases, disorders, or conditions.
摘要翻译：本发明涉及系统A转运抑制剂，拮抗剂，衍生物或其模拟物，以及它们作为用于治疗或预防神经精神疾病，病症或病症（包括精神分裂症）的化合物，药物或药剂的用途。本发明的另一个实施方案涉及鉴定或筛选用于治疗或预防神经精神疾病，病症或病症的该系统A转运抑制剂的方法。

3. 发明申请

WO2005018424A2 ANTIBODIES SPECIFIC FOR FIBRILLAR AMYLOID AND A PROCEDURE TO DETECT FIBRILLAR AMYLOID DEPOSITS 审中-公开
标题翻译：针对纤维青霉素的特异性抗体和检测纤维淀粉样沉积物的方法
公开(公告)号：WO2005018424A2
公开(公告)日：2005-03-03
申请号：PCT/US2004026661
申请日：2004-08-18
申请人： RES FOUND MENTAL HYGIENE , MILLER DAVID L , MEHTA PANKAJ , WEGIEL JERZY
发明人： MILLER DAVID L , MEHTA PANKAJ , WEGIEL JERZY
IPC分类号： C07K16/18 , A61B
CPC分类号： C07K16/18 , C07K2317/55
摘要： The present invention provides novel antibodies, and antibody fragments, that specifically bind to fibrillar amyloid, and not to the non-fibrillar peptide. Also provided are methods for generating, identifying, and isolating the antibodies and antibody fragments of the invention. The antibodies described herein are useful in the study, diagnosis, and treatment of Alzheimer's disease.
摘要翻译：本发明提供特异性结合纤维状淀粉样蛋白而不是非纤维状肽的新型抗体和抗体片段。还提供了用于产生，鉴定和分离本发明的抗体和抗体片段的方法。本文描述的抗体可用于阿尔茨海默病的研究，诊断和治疗。

4. 发明申请

WO02065093A3 METHODS AND COMPOSITIONS OF AMPLIFYING RNA 审中-公开
标题翻译：扩增RNA的方法和组合物
公开(公告)号：WO02065093A3
公开(公告)日：2002-10-10
申请号：PCT/US0205713
申请日：2002-02-14
申请人： BAYLOR COLLEGE MEDICINE , RES FOUND MENTAL HYGIENE , GINSBERG STEPHEN D , CHE SHAOLI
发明人： GINSBERG STEPHEN D , CHE SHAOLI
IPC分类号： C12N15/09 , C12P19/34 , C12Q1/68 , G01N20060101
CPC分类号： C12Q1/6865 , C12Q2563/107 , C12Q2525/185 , C12Q2525/179
摘要： The present invention pertains to a method that will increase the efficiency of second strand cDNA synthesis through a mechanism of "terminal continuation" before further RNA amplification by RNA transcription using, for example, a bacteriophage promoter. In a specific embodiment, a transcription promoter is attached to the 5' region of cDNA through the same mechanism of "terminal continuation". Genetic signals are subsequently amplified in a linear manner through RNA transcription. In specific embodiments, the orientation of the transcribed RNA is either sense or antisense, depending on the desired downstream application. In other embodiments, the present invention pertains to methods for extraction and amplification of RNA, particularly mRNA, from histologically stained tissues and cells.
摘要翻译：本发明涉及通过使用例如噬菌体启动子通过RNA转录进一步进行RNA扩增之前通过“末端连续”机制来提高第二链cDNA合成效率的方法。在一个具体的实施方案中，转录启动子通过“末端连续”的相同机制附着于cDNA的5'区域。随后通过RNA转录以线性方式扩增遗传信号。在具体的实施方案中，取决于期望的下游应用，转录的RNA的取向是有义或反义的。在其他实施方案中，本发明涉及从组织学染色的组织和细胞中提取和扩增RNA，特别是mRNA的方法。

5. 发明申请

WO2005021711A3 APPROACH FOR OBTAINING MONOCLONAL ANTIBODIES TO CELL SURFACE PROTEINS 审中-公开
标题翻译：用于获得单克隆抗体对细胞表面蛋白的方法
公开(公告)号：WO2005021711A3
公开(公告)日：2005-05-26
申请号：PCT/US2004019217
申请日：2004-06-16
申请人： RES FOUND MENTAL HYGIENE , RUBENSTEIN RICHARD , KASCSAK RICHARD , KIM JAE-IL , KURIZON SOLOMON , PETERSEN ROBERT , SY MAN-SUN
发明人： RUBENSTEIN RICHARD , KASCSAK RICHARD , KIM JAE-IL , KURIZON SOLOMON , PETERSEN ROBERT , SY MAN-SUN
IPC分类号： C07K16/18 , C07K16/28 , C12N20060101 , C12N5/18 , C12N5/20 , C12P21/08
CPC分类号： C07K16/2872
摘要： The present invention provides a novel method for producing monoclonal antibodies against a variety of mammalian antigens, and in particular, cell surface antigens that are relatively conserved between species. In a specific embodiment, the invention relates to the generation of monoclonal antibodies that specifically react with prion proteins (PrP). The method comprises combining a PrP knockout mouse and a PrP-non-expressing fusion partner for hybridoma production, thereby opening all regions and conformation of the molecule to antibody production. This approach leads to many new and useful monoclonal antibodies of varying specificities.
摘要翻译：本发明提供了产生针对多种哺乳动物抗原的单克隆抗体的新方法，特别是在物种间相对保守的细胞表面抗原。在具体的实施方案中，本发明涉及与朊病毒蛋白（PrP）特异性反应的单克隆抗体的产生。该方法包括将PrP敲除小鼠和PrP-非表达融合伴侣组合用于杂交瘤生产，从而打开分子的所有区域和构象以产生抗体。这种方法导致许多具有不同特异性的新的和有用的单克隆抗体。

6. 发明申请

WO0169260A2 A LYSOSOMAL PEPSTATIN-INSENSITIVE PROTEINASE AS A NOVEL BIOMARKER FOR DETECTING AND DIAGNOSING BREAST CANCER 审中-公开
标题翻译：作为检测和诊断乳腺癌的新型生物标记物的LYSOSOMAL PEPSTATIN-INSENSITIVE PROTEINASE
公开(公告)号：WO0169260A2
公开(公告)日：2001-09-20
申请号：PCT/US0107393
申请日：2001-03-08
申请人： RES FOUND MENTAL HYGIENE , PULLARKAT RAJU K , JUNAID MOHAMMAD A
发明人： PULLARKAT RAJU K , JUNAID MOHAMMAD A
IPC分类号： C12Q1/37 , G01N33/543 , G01N33/573 , G01N33/574 , G01N33/577 , G01N33/58
CPC分类号： G01N33/57415 , C12Q1/37
摘要： The present invention describes diagnostic and prognostic assays to detect in vascular and tissue samples the presence and activity of the lysosomal pepstatin-insensitive proteinase, CLN2p, which has been newly found to be associated with breast cancer and serves as a novel biomarker for breast cancer, including primary, non-primary, or metastatic breast tumors, neoplasms and carcinomas. The activity of CLN2p was discovered to be significantly elevated when measured in breast tissue samples from patients with primary breast carcinoma, compared with CLN2p levels in normal sample controls, thereby demonstrating an approximately two- to seventeen-fold higher CLN2p activity in breast tumors. These higher levels of CLN2p activity in breast tumors were positively correlated with several known breast cancer biomarkers, such as cathepsin D, estrogen receptor and progesterone receptor. The present invention thus provides CLN2p as new biomarker for use in the detection, diagnosis and prognosis of breast cancer.
摘要翻译：本发明描述了在血管和组织样品中检测溶酶体胃酶抑素不敏感蛋白酶CLN2p的存在和活性的诊断和预后测定法，CLN2p已被新发现与乳腺癌相关并且用作乳腺癌的新型生物标志物，包括原发性，非原发性或转移性乳腺肿瘤，肿瘤和癌。在正常样本对照中与CLN2p水平相比，CLN2p的活性在原发性乳腺癌患者的乳腺组织样本中测量时发现显着升高，从而证明了乳腺肿瘤中CLN2p活性高达二至十七倍。乳腺肿瘤中这些更高水平的CLN2p活性与几种已知的乳腺癌生物标志物如组织蛋白酶D，雌激素受体和孕酮受体呈正相关。因此，本发明提供了CLN2p作为用于乳腺癌的检测，诊断和预后的新的生物标志物。

7. 发明申请

WO2004035753B1 LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS 审中-公开
标题翻译： LMNA基因及其在HUTCHINSON-GILFORD PROGERIA SYNDROME（HGPS）和ARTERIOSCLEROSIS中的参与
公开(公告)号：WO2004035753B1
公开(公告)日：2005-03-10
申请号：PCT/US0333058
申请日：2003-10-17
申请人： US GOV HEALTH & HUMAN SERV , PROGERIA RES FOUNDATION INC , RES FOUND MENTAL HYGIENE , ERIKSSON MARIA B H , COLLINS FRANCIS S , GORDON LESLIE B , BROWN TED W
发明人： ERIKSSON MARIA B H , COLLINS FRANCIS S , GORDON LESLIE B , BROWN TED W
IPC分类号： C07K14/47 , C12Q1/68 , C07H21/04 , C07K14/78 , G01N33/53
CPC分类号： C07K14/47 , C12Q1/6883 , C12Q1/6886 , C12Q2600/136 , C12Q2600/156 , G01N2500/04 , Y10T436/143333
摘要： Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon (11) and generation of a mutant Lamin A protein product that is (50) amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described. Oligonucleotides and other compounds for use in examples of the described methods are also provided, as are protein-specific binding agents, such as antibodies, that bind specifically to at least one epitope of a Lamin A variant protein preferentially compared to wildtype Lamin A, and methods of using such antibodies in diagnosis, treatment, and screening. Also provided are kits for carrying out the methods described herein.
摘要翻译：本文公开了导致HGPS的LMNA基因中的点突变。这些突变激活了LMNA基因内的隐性剪接位点，导致部分外显子（11）的缺失和产生比正常蛋白质短（50）氨基酸的突变Lamin A蛋白产物。除了新型Lamin A变体蛋白和编码该变体的核酸之外，使用这些分子检测与受试者的LMNA突变相关的生物学条件（例如，HGPS，动脉硬化和其他与年龄相关的疾病）的方法，还描述了治疗这些病症，选择治疗方法，筛选影响Lamin A活性的化合物的方法，以及影响LMNA或LMNA变体表达的方法。还提供了用于所述方法的实施例的寡核苷酸和其它化合物，以及优选与野生型Lamin A相比特异性结合Lamin A变体蛋白的至少一个表位的蛋白质特异性结合剂，例如抗体，以及在诊断，治疗和筛查中使用这些抗体的方法。还提供了用于实施本文所述方法的试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式